Ajovy Market Report 2026

Ajovy Market Overview

• The Ajovy market growth in the historic period has been driven by high unmet need in migraine care, approval of cgrp biologics • Market expansion is supported by increase in episodic migraine diagnosis, expansion of preventive treatment guidelines • Growth Driver: Rising Prevalence Of Migraines Driving Growth In The Ajovy Market • Market Trend: Advanced Monoclonal Antibody Syringes For Enhanced Migraine Prevention • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ajovy Market?

Ajovy is a monoclonal antibody used to prevent chronic and episodic migraines in adults. It works by blocking the calcitonin gene-related peptide (CGRP) receptor, which plays a key role in migraine attacks. By inhibiting CGRP, Ajovy helps reduce both the frequency and severity of migraines. The main types of clinical indications for ajovy are migraine prevention and cluster headache prevention. Migraine prevention with Ajovy helps reduce the frequency, duration, and intensity of attacks, offering relief and improving the quality of life for patients with chronic migraines. It is distributed through several distribution channels, such as hospitals and clinics, retail, and specialty pharmacies, and used by various end-users, including adults and geriatric.

What Is The Ajovy Market Growth Forecast?

The growth in the forecast period can be attributed to increase in episodic migraine diagnosis, expansion of preventive treatment guidelines, rising biologics acceptance, broader reimbursement access, growing patient education initiatives. Major trends in the forecast period include rising adoption of cgrp monoclonal antibodies, growth of preventive migraine therapies, preference for long acting injection regimens, expansion of self administration models, increased awareness of migraine as a chronic disease.

Global Ajovy Market Segmentation

1) By Clinical Indication: Migraine Prevention, Cluster Headache Prevention 2) By Distribution Channel: Hospital And Clinics, Retail And Specialty Pharmacies 3) By End-User: Adult, Geriatric

What Is The Driver Of The Ajovy Market?

The increasing prevalence of migraine cases is expected to propel the growth of the ajovy market moving forward. Migraine is a neurological condition characterized by recurrent, severe headaches, often accompanied by symptoms such as nausea, vomiting, and sensitivity to light and sound. The number of migraine cases is increasing due to factors such as rising stress levels, lifestyle changes, environmental factors, and genetic predisposition. Ajovy helps decrease the frequency and intensity of migraine attacks, offering relief to individuals experiencing chronic or episodic migraines. For instance, in March 2024, according to The House of Commons Library, a UK-based research and information service, around 10 million individuals in the UK are affected by migraines. According to The Migraine Trust, more than one million people suffer from chronic migraines, experiencing symptoms on at least 15 days per month. Therefore, the increasing prevalence of migraine cases is driving the growth of the Ajovy industry.

Key Players In The Global Ajovy Market

Major companies operating in the ajovy market are Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd.

Global Ajovy Market Trends and Insights

The key trend in the ajovy market is focusing on developing advanced monoclonal antibody syringes to improve ease of use, ensure accurate dosing, and enhance patient adherence to migraine prevention therapies. Monoclonal antibody syringes are pre-filled syringes containing lab-engineered monoclonal antibodies, designed to precisely target specific antigens involved in various diseases. For instance, Otsuka Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, launched the AJOVY Subcutaneous Injection 225 mg Syringe. It is an anti-CGRP monoclonal antibody designed for migraine prevention and was developed using recombinant DNA technology. By targeting the CGRP ligand and preventing its interaction with receptors, it helps reduce the frequency of migraine attacks. Administered through subcutaneous injection, it offers flexible dosing schedules: 225 mg every four weeks or 675 mg every 12 weeks, setting it apart within its class.

What Are Latest Mergers And Acquisitions In The Ajovy Market?

In June 2024, Lotus Pharmaceuticals, a Taiwan-based pharmaceutical company, acquired Teva Pharmaceutical's Thailand operations for an undisclosed amount. The acquisition aims to strengthen Lotus’ presence in Southeast Asia, expand its portfolio in oncology, women's health, ophthalmology, and respiratory products, and enhance its reach in both hospital and pharmacy channels to drive sustained profit growth and healthcare accessibility in the region. Teva Pharma (Thailand) Company Limited is a Thailand-based pharmaceutical company that offers treatments for migraines and other central nervous system (CNS) disorders.

Regional Insights

North America was the largest region in the ajovy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Ajovy Market?

The ajovy market consists of sales of fremanezumab injections, autoinjectors, pre-filled syringes, and pre-mixed injection solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ajovy Market Report 2026?

The ajovy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ajovy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.